What is the recommended treatment for stable angina?

Treatment of Stable Angina

All patients with stable angina should receive short-acting sublingual nitroglycerin for acute symptom relief, plus a beta-blocker as first-line therapy titrated to full dose, combined with aspirin 75-150 mg daily and statin therapy for cardiovascular event prevention. 1

Dual Treatment Goals

Treatment of stable angina requires addressing two distinct objectives that cannot be achieved with the same medications 1:

• Symptom relief and quality of life improvement: Anti-anginal drugs (beta-blockers, calcium channel blockers, nitrates)
• Prevention of cardiovascular events (MI and death): Aspirin, statins, and ACE inhibitors

Importantly, symptomatic therapy does not improve prognosis, and prognostic therapy does not alleviate symptoms 1.

First-Line Pharmacological Strategy

Immediate Symptom Management

• Short-acting nitroglycerin (sublingual or buccal) for acute symptom relief and situational prophylaxis, with proper patient education on use 1

Primary Anti-Anginal Therapy

• Beta-1 blocker as initial monotherapy, titrated to full dose with consideration for 24-hour ischemia protection 1
• Beta-blockers are particularly indicated in patients with post-MI status, heart failure, hypertension, or elevated heart rate 1, 2
• Relative contraindications include asthma, symptomatic peripheral vascular disease, and first-degree heart block 1

Disease-Modifying Therapy (Mandatory for All Patients)

• Aspirin 75-150 mg daily for cardiovascular event prevention 1
• Statin therapy (high-dose per some guidelines, or target LDL approach) 1, 3
• ACE inhibitor in patients with ventricular dysfunction, hypertension, diabetes, or other high-risk features 1

Escalation Algorithm When Beta-Blocker Monotherapy Fails

If Beta-Blocker Intolerant or Contraindicated

Switch to monotherapy with 1:

• Calcium channel blocker (Level A evidence)
• Long-acting nitrate (Level C evidence), or
• Nicorandil (Level C evidence)

If Beta-Blocker Insufficient After Dose Optimization

• Add dihydropyridine calcium channel blocker (Level B evidence) 1
• Avoid short-acting dihydropyridine formulations without beta-blocker coverage 1

If Two-Drug Combination Fails

• Substitute the calcium channel blocker with a long-acting nitrate or nicorandil 1
• Be vigilant about nitrate tolerance with long-acting preparations 1
• Consider revascularization at this stage if symptoms remain uncontrolled 1

Important Caveats

Optimize dosing of one drug before adding another - poor adherence and inadequate dosing are common reasons for treatment failure 1. It is advisable to switch drug combinations before attempting three-drug regimens 1.

No anti-anginal drug is superior to another - systematic review of 50 years of evidence shows equivalence among beta-blockers, calcium channel blockers, and ivabradine, with no drug demonstrating superiority in exercise duration or angina relief 4. Despite this, guidelines preferentially recommend beta-blockers and calcium channel blockers as first-line based on clinical consensus rather than comparative efficacy data 4, 5.

Microvascular angina may account for up to 40% of angina cases and can persist after successful revascularization 1. These patients require different management approaches targeting coronary microvascular dysfunction 1.

Special Consideration: Vasospastic Angina

For vasospastic angina, the treatment approach differs 1:

• Calcium channel blockers are more effective than nitrates for prevention (high doses: verapamil up to 480 mg/day, diltiazem up to 260 mg/day, nifedipine up to 120 mg/day) 1
• Combination therapy with long-acting nitrates and high-dose calcium antagonists is usually required 1
• Smoking cessation is essential 1
• Spontaneous remission occurs in approximately 50% of patients after 1 year of treatment, allowing consideration of tapering therapy at 6-12 months if asymptomatic 1

Revascularization Considerations

Coronary revascularization does not reduce mortality or MI risk compared to optimal medical therapy alone, even in moderate to severe ischemia 3. However, revascularization provides meaningful benefit for angina symptoms and quality of life 3. Reserve revascularization for patients whose angina negatively impacts quality of life despite optimized medical therapy 3.